Sofosbuvir archivos - Fundación GEP

FGEP continues defense of public health in Argentina against the abuse of the patent system by multinational pharmaceutical companies

Fundación GEP2015-12-17T03:50:58-03:00jueves, 17 diciembre, 2015|Access to Medicines, Argentina, Direct Action, Health Safeguards, HIV, Intellectual Property, Kaletra, Patent opposition, Sofosbuvir|

BUENOS AIRES, December 15th 2015 - Fundación Grupo Efecto Positivo (FGEP), an organization whose work is focused on guaranteeing access to essential medicines for HIV and Hepatitis C in Argentina and Latin America, announced in a press conference on November 30th two new key actions to defend public health policies. Dr. Daniel Gollán, Argentina’s Minister

Regulatory Agency in Argentina approved sofosbuvir and a local pharmaceutical company announced the entry into the market of its generic version

Buenos Aires, November 10, 2015 - Argentine Medicines Regulatory Agency, ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) approved last week commercialization of a relevant medicine to treat Hepatitis C. “This measure was highly expected since it is the first step to ensure availability of this essential medicine in our country. I live with Hepatitis